Filamin A binding proteins and uses thereof
AssigneeBPGbio, Inc.
InventorsWenfang Sybil Wu, Shobha Ravipaty, Tracey Friss, Viatcheslav R. Akmaev, Nikunj Narendra Tanna
Life of this patent
Estimating the term…
Abstract
The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.
Claims11
A method for detecting and/or quantifying the level of FLNA in a sample, comprising contacting the sample with an antibody construct, or antigen-binding fragment thereof, capable of binding filamin A (FLNA) comprising
- (i) a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 9, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 8, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 7, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 12, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 10;
- or
- (ii) a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 15, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 14, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 13, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 18, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 17, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 16;
- or
- (iii) a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 21, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 20, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 19, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 24, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 23, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 22 under conditions such that the antibody construct or antigen-binding fragment thereof binds to FLNA in the sample, to thereby detect and/or quantify the level of FLNA in a sample.
A method for detecting and/or quantifying the level of FLNA in a sample, comprising detecting and/or quantifying one or more surrogate peptides, wherein the one or more surrogate peptides comprise the amino acid sequence of SEQ ID NO:40 (P2) and/or SEQ ID NO:41 (P4), in a protein digest prepared from said sample using mass spectrometry, wherein the mass spectrometry is multiple reaction monitoring (MRM) mass spectrometry, wherein the MRM is immunoprecipitation-multiple reaction monitoring (IPMRM) comprising a FLNA immunoprecipitation step, and wherein the immunoprecipitation step is carried out using an antibody construct, or antigen-binding fragment thereof, capable of binding filamin A (FLNA) comprising
- (i) a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 9, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 8, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 7, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 12, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 10;
- or
- (ii) a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 15, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 14, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 13, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 18, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 17, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 16;
- or
- (iii) a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 21, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 20, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 19, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 24, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 23, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 22.
Dependencies are inferred from the claim text.